{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:28Z","timestamp":1792036828858,"version":"4.4.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.xjidi.2023.100220","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T21:13:43Z","timestamp":1691615623000},"page":"100220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5728-9875","authenticated-orcid":false,"given":"Erica","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7643-0061","authenticated-orcid":false,"given":"Mariam","family":"Abdelghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0167","authenticated-orcid":false,"given":"Bridget E.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0975-4071","authenticated-orcid":false,"given":"William","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2023.100220_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2020.12.021","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil","volume":"9","author":"Alam","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.04.005","article-title":"Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis","volume":"152","author":"Arger","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105822","article-title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis","volume":"161","author":"Arger","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib4","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1111\/ajd.13858","article-title":"Treatment of generalized granuloma annulare with tildrakizumab","volume":"63","author":"Awad","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.01.001","article-title":"Remission of necrobiosis lipoidica diabeticorum with a JAK1\/2 inhibitor: a case report","volume":"47","author":"Barbet-Massin","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.xjidi.2023.100220_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamadermatol.2021.1847","article-title":"Incidence and prevalence of granuloma annulare in the United States","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamadermatol.2021.1805","article-title":"Association of granuloma annulare with Type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jaad.2021.04.098","article-title":"Granuloma annulare is not associated with solid-organ malignancies: a cohort study","volume":"86","author":"Barbieri","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000328403","article-title":"Intralesional infliximab in noninfectious cutaneous granulomas: three cases of necrobiosis lipoidica","volume":"222","author":"Barde","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100220_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.metabol.2015.12.014","article-title":"Anti-TNF\u03b1 treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: a case report and review of the literature","volume":"65","author":"Basoulis","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.xjidi.2023.100220_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib13","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.xjidi.2023.100220_bib14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.xjidi.2023.100220_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib16","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1111\/ajd.13643","article-title":"Ulcerating necrobiosis lipoidica successfully treated with ustekinumab","volume":"62","author":"Beatty","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jamadermatol.2019.2130","article-title":"Refractory generalized granuloma annulare treated with oral apremilast","volume":"155","author":"Bishnoi","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jdcr.2019.09.015","article-title":"Treatment of generalized granuloma annulare with apremilast: a report of 2 cases","volume":"5","author":"Blum","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib19","article-title":"A\u00a0case of granuloma annulare associated with secukinumab use","volume":"2017","author":"Bonomo","year":"2017","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ajd.13875","article-title":"Treatment of granuloma annulare with tofacitinib","volume":"63","author":"Bosch-Amate","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/1346-8138.14981","article-title":"Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3-positive cells in granuloma annulare","volume":"46","author":"B\u00fcrgler","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ijd.14350","article-title":"The role of biologics in the treatment of chronic granuloma annulare","volume":"58","author":"Chen","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/bjd\/ljac004","article-title":"Patient perspectives on the lived experience of granuloma annulare","volume":"188","author":"Clark","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib24","article-title":"Granuloma annulare in the setting of secukinumab","volume":"2018","author":"Clark","year":"2018","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2021.12.016","article-title":"Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib","volume":"98","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02695-2020","article-title":"Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis","volume":"57","author":"Crouser","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.xjidi.2023.100220_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-4632.2004.02120.x","article-title":"Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy","volume":"43","author":"Cummins","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2019.10.016","article-title":"Treatment of granuloma annulare with tofacitinib 2% ointment","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdcr.2019.11.016","article-title":"Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib32","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib34","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2023.100220_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of multiorgan sarcoidosis with tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib36","first-page":"1298","article-title":"JAK inhibitor safety compared to traditional systemic immunosuppressive therapies","volume":"21","author":"Daniele","year":"2022","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0560.2007.00854.x","article-title":"Immunohistochemical features of cutaneous granulomas in primary immunodeficiency disorders: a comparison with cutaneous sarcoidosis","volume":"35","author":"de Jager","year":"2008","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.xjidi.2023.100220_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15188","article-title":"Is biologic therapy the future of granuloma annulare treatment?","volume":"35","author":"Dopytalska","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2023.100220_bib39","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/120347540300700503","article-title":"Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses","volume":"7","author":"Drosou","year":"2003","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2023.100220_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jdcr.2020.07.054","article-title":"Generalized granuloma annulare: a widespread response to limited application of compounded 2% topical tofacitinib","volume":"6","author":"Durgin","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib42","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/jdv.16297","article-title":"Successful treatment of ulcerative necrobiosis lipoidica with Janus kinase inhibitor","volume":"34","author":"Erfurt-Berge","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2023.100220_bib43","series-title":"Clinical Trials","year":"2018"},{"key":"10.1016\/j.xjidi.2023.100220_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1440-1746.2009.06098.x","article-title":"Education and imaging. Gastrointestinal: improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease","volume":"25","author":"Fanning","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib45","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jdcr.2020.07.013","article-title":"Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab","volume":"6","author":"F\u00e4ssler","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s004030000150","article-title":"Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare","volume":"292","author":"Fayyazi","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xjidi.2023.100220_bib47","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/rheumatology\/kez055","article-title":"Necrobiosis lipoidica with bone involvement successfully treated with infliximab","volume":"58","author":"Fertitta","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2023.100220_bib48","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049888","article-title":"Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature","volume":"26","author":"Fox","year":"2020","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2023.100220_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jdcr.2018.03.007","article-title":"Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa","volume":"4","author":"Friedman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.xjidi.2023.100220_bib51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/ced.14579","article-title":"Granuloma annulare following initiation of interleukin-17a antagonist","volume":"46","author":"Gray","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.xjidi.2023.100220_bib53","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1164\/rccm.202004-0914IM","article-title":"Successful response to treatment with sirolimus in pulmonary sarcoidosis","volume":"202","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib54","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/ced.14806","article-title":"Generalized granuloma annulare successfully treated with apremilast: report of two cases and literature review","volume":"46","author":"Hansel","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib55","doi-asserted-by":"crossref","DOI":"10.5070\/D3237035756","article-title":"Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica: case report and proposed mechanism","volume":"23","author":"Hassoun","year":"2017","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2023.100220_bib56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamadermatol.2017.1162","article-title":"Efficacy and tolerance of anti\u2013tumor necrosis factor \u03b1 agents in cutaneous sarcoidosis: a French study of 46 cases","volume":"153","author":"Heidelberger","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib58","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/jdv.16451","article-title":"Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis","volume":"34","author":"Hornick","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2023.100220_bib59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archdermatol.2009.6","article-title":"Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case","volume":"145","author":"Hu","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib60","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.xjidi.2023.100220_bib61","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1111\/jdv.18031","article-title":"Successful treatment of generalized granuloma annulare with baricitinib","volume":"36","author":"Yan","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2023.100220_bib62","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ijd.15960","article-title":"Ulcerated necrobiosis lipoidica successfully treated with tofacitinib","volume":"61","author":"Jan\u00dfen","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib63","article-title":"Apremilast in the management of disseminated granuloma annulare","volume":"13","author":"Joshi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.xjidi.2023.100220_bib64","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2011.06.017","article-title":"Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway","volume":"66","author":"Judson","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1346-8138.12477","article-title":"Necrobiosis lipoidica with infiltration of Th17 cells into vascular lesions","volume":"41","author":"Kato","year":"2014","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235372","article-title":"Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus","volume":"13","author":"Kelleher","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.xjidi.2023.100220_bib71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000068465","article-title":"Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica","volume":"206","author":"Kolde","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100220_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/12034754211048679","article-title":"Generalized granuloma annulare: a retrospective study from Southern Ontario, Canada","volume":"26","author":"Lam","year":"2022","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2023.100220_bib73","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1111\/bcp.14878","article-title":"Lung and liver sarcoidosis-like reaction induced by tocilizumab","volume":"87","author":"Lambert","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xjidi.2023.100220_bib74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/jamadermatol.2018.0756","article-title":"Improvement in ulcerative necrobiosis lipoidica after Janus kinase\u2013inhibitor therapy for polycythemia Vera","volume":"154","author":"Lee","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib75","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to Ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2023.100220_bib76","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1183\/13993003.01469-2015","article-title":"Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis","volume":"47","author":"Li","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib77","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib78","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.semarthrit.2017.09.010","article-title":"Blau syndrome with good Reponses to tocilizumab: a case report and focused literature review","volume":"47","author":"Lu","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2023.100220_bib79","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/j.1432-2277.2011.01256.x","article-title":"Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of Rapamune after liver transplantation","volume":"24","author":"Manzia","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.xjidi.2023.100220_bib80","article-title":"Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report","volume":"9","author":"McPhie","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib81","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1046\/j.1523-1747.2002.01783.x","article-title":"T-cell receptor repertoire and cytokine pattern in granuloma annulare: defining a particular type of cutaneous granulomatous inflammation","volume":"118","author":"Mempel","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib82","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaad.2019.12.028","article-title":"Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways","volume":"83","author":"Min","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"Mirsaeidi","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.xjidi.2023.100220_bib84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.xjidi.2023.100220_bib85","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.abd.2019.04.003","article-title":"Perforating necrobiosis lipoidica: good response to adalimumab","volume":"94","author":"Nunes de Mattos","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaad.2018.06.024","article-title":"Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: postmarketing analysis from the RADAR (\"Research on Adverse Drug events And Reports\") program","volume":"79","author":"Orrell","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib87","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib88","article-title":"Generalized granuloma annulare associated with dupilumab therapy","volume":"14","author":"Phelps-Polirer","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.xjidi.2023.100220_bib89","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2015.03.054","article-title":"Granuloma annulare: clinical and histologic variants, epidemiology, and genetics","volume":"75","author":"Piette","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib90","doi-asserted-by":"crossref","DOI":"10.5070\/D3258045141","article-title":"Treatment-resistant ulcerative necrobiosis lipoidica in a diabetic patient responsive to ustekinumab","volume":"25","author":"Pourang","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2023.100220_bib91","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaad.2013.05.034","article-title":"Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options","volume":"69","author":"Reid","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib92","series-title":"Dermatology","first-page":"1644","article-title":"Noninfectious granulomas","author":"Rosenbach","year":"2018"},{"key":"10.1016\/j.xjidi.2023.100220_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clim.2009.04.010","article-title":"Hypothesis: sarcoidosis is a STAT1-mediated disease","volume":"132","author":"Rosenbaum","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib94","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under Ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib95","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/rheumatology\/kes377","article-title":"Sarcoid-like granulomatosis in a patient treated by interleukin-1 receptor antagonist for TNF-receptor-associated periodic syndrome","volume":"52","author":"Sacre","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.xjidi.2023.100220_bib96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.xjidi.2023.100220_bib97","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.xjidi.2023.100220_bib98","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2020-217271","article-title":"Steroid-resistant sarcoidosis treated with baricitinib","volume":"79","author":"Scheinberg","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2023.100220_bib99","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib100","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir Med X"},{"key":"10.1016\/j.xjidi.2023.100220_bib101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs","volume":"166","author":"Shigehara","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib102","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jdcr.2020.11.016","article-title":"Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy","volume":"7","author":"Singh","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15211","article-title":"Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a patient with rheumatoid arthritis","volume":"35","author":"Sondermann","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2023.100220_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2020.10.021","article-title":"Recalcitrant generalized granuloma annulare treated successfully with dupilumab","volume":"7","author":"Song","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib105","first-page":"17","article-title":"Generalized granuloma annulare successfully treated with ustekinumab","volume":"14","author":"Song","year":"2021","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2020.10.034","article-title":"Tildrakizumab ineffective in generalized granuloma annulare","volume":"7","author":"Song","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.xjidi.2023.100220_bib108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000314694","article-title":"Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature","volume":"221","author":"Su\u00e1rez-Amor","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100220_bib109","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"31","author":"Sweiss","year":"2014","journal-title":"World Assoc Sarcoidosis Granulomatous Disord"},{"key":"10.1016\/j.xjidi.2023.100220_bib110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"Talty","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib111","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.xjidi.2023.100220_bib112","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.xjidi.2023.100220_bib113","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ijd.14909","article-title":"Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon","volume":"59","author":"Theodosiou","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100220_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.xjidi.2023.100220_bib115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xjidi.2023.100220_bib116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/00015555-1502","article-title":"Pigmented necrobiosis lipoidica accompanied by insulin-dependent diabetes mellitus induces CD163\u207a proinflammatory macrophages and interleukin-17-producing cells","volume":"93","author":"Wakusawa","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2023.100220_bib117","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jaci.2020.10.012","article-title":"Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib","volume":"147","author":"Wang","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2023.100220_bib118","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature","volume":"93","author":"Wang","year":"2020","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib119","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107055","article-title":"Durable medication-free remission of sarcoidosis following discontinuation of Anti-tumor Necrosis Factor-alpha therapy","volume":"206","author":"Yee","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.xjidi.2023.100220_bib121","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12969-021-00634-x","article-title":"Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients","volume":"19","author":"Zhang","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.xjidi.2023.100220_bib122","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2023.100220_bib123","article-title":"Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:04:43Z","timestamp":1763021083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026723000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2667026723000450"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100220","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100220"}}